Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting

Core Insights - Xilio Therapeutics, Inc. is set to present initial data from its Phase 1C dose escalation study of XTX101 in combination with atezolizumab for patients with advanced solid tumors at the SITC 39th Annual Meeting in Houston, Texas from November 6-10, 2024 [1][2] Company Overview - Xilio Therapeutics is a clinical-stage biotechnology company focused on developing tumor-activated immuno-oncology therapies aimed at improving cancer treatment outcomes while minimizing systemic side effects [3] - The company utilizes a proprietary platform to advance a pipeline of novel tumor-activated clinical and preclinical immuno-oncology molecules, including cytokines, antibodies, bispecifics, and immune cell engagers [3] Clinical Trial Details - The upcoming poster presentation will detail a Phase 1/2 study of vilastobart (formerly XTX101), an investigational anti-CTLA-4 monoclonal antibody, in combination with atezolizumab for patients with advanced solid tumors [2] - The trial is co-funded in collaboration with Roche and aims to evaluate the safety and efficacy of the combination treatment, particularly in patients with microsatellite stable colorectal cancer [2]